Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Mesenchymal Stem Cells for Systemic Lupus Erythematosus
NCT03171194Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in systemic lupus erythematosus (SLE), sponsored by Medical University of South Carolina. Primary endpoint: Frequency of Grade 3 or higher adverse events at Week 24. Started Apr 2017; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03171194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171194.